Insulin therapies - Past, present and future

Drug Discovery Today

Volumn 6, Issue 20, 2001, Pages 1056-1061

  Pillai, Omathanu ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE;

BIOTECHNOLOGY; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG RELEASE; DRUG RESEARCH; HUMAN; INSULIN PUMP; REVIEW;

EID: 0035888373     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01962-6     Document Type: Review

References (65)

1. Insulin to human insulin
2. The new insulins. Their characteristics and clinical indications
3. Recent approaches in insulin delivery
4. Immunoassay of endogenous plasma insulin in man
5. Drug delivery - an odyssey of 100 years
6. Drug discovery: a historical perspective
7. Quo vadis, biotech? - Part 1
8. Monomeric insulins and their experimental and clinical implications
9. Insulin analogues: new agents for improving glycemic control
10. Genetically engineered insulin analogs. Diabetes in the new millennium
11. Dissecting human disease in the postgenomic era
12. New insulin delivery systems key to diabetes management, compliance
13. Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment
14. Insulin delivery using pen devices
15. Pharmacokinetic considerations of new insulin formulations and routes of administration
16. Tennis anyone? The lungs as a new court for systemic therapy
17. Inhaled insulin
18. Oral insulin delivery
19. Oral delivery of insulin by using surface coating liposomes. Improvement of stability of insulin in GI tract
20. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carriers
21. Design and in vivo evaluation of an oral delivery system for insulin
22. A new approach for the oral administration of insulin and other peptide drugs
23. The physiological replacement of insulin - an elusive goal
24. Insulin and atherosclerosis
25. Insulin and the gastrointestinal tract
26. Rectal administration of insulin
27. A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design
28. Clinical control of diabetes by the artificial pancreas
29. Control of blood glucose in experimental diabetes by means of a totally implantable insulin infusion device
30. Implantable insulin pumps
31. On behalf of the EVIDAC group. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM
32. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM?
33. Controlled drug delivery in the treatment of diabetes mellitus
34. Responsive polymeric delivery systems
35. A sweeter life for diabetics?
36. Iontophoresis revisited
37. Towards gene therapy of diabetes mellitus
38. Extracellular matrix for a rechargeable cell delivery system
39. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
40. Development of engineered pancreatic β-cell lines for cell therapy of diabetes
41. Glucose responsive gene delivery in pancreatic islet cells via recombinant adeno-associated viral vectors
42. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
43. Insulin analogs with improved pharmacokinetic profile
44. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
45. Remission in models of type 1 diabetes by gene therapy using a single-chain analogue
46. Microchips as controlled drug delivery devices
47. Microfabricated microneedles. A novel approach to transdermal drug delivery
48. Pancreatic extracts
49. Crystalline insulin
50. Crystalline insulin
51. Protamine insulinate
52. Crystalline and amorphous insulin-zinc compounds with prolonged action
53. Chemistry of insulin
54. Structure of rhombohedral 2 zinc insulin crystals
55. Expression in Escherichia coli of chemically synthesized genes for human insulin
56. Lispro insulins. Benefits and limitations
57. Improved postprandial glycemic control with insulin aspart. type 1 diabetes
58. Insulin glargine
59. Acylation of human insulin with palmitic acid extends the time of action of human insulin in diabetic dogs
60. Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs
61. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase